Anti-viral T-cell Therapy by Gamma Capture

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2029

Conditions
AdenovirusCytomegalovirus InfectionsEpstein-Barr Virus Infections
Interventions
BIOLOGICAL

Specific T- Lymphocytes

Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.

Trial Locations (1)

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

All Listed Sponsors
lead

Paul Szabolcs

OTHER